We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.52B
AUM Growth
-$648M
Cap. Flow
+$87.1M
Cap. Flow %
1.58%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$349M
2
PGNY icon
Progyny
PGNY
+$22.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Miscellaneous 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$350M 6.33%
+2,718,735
New +$349M
BMY icon
2
Bristol-Myers Squibb
BMY
$131B
$194M 3.51%
2,518,700
-89,000
-3% -$6.78M
HUM icon
3
Humana
HUM
$48.9B
$171M 3.1%
365,700
-16,000
-4% -$7.12M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$168M 3.05%
2,108,555
-88,000
-4% -$8.33M
BSX icon
5
Boston Scientific
BSX
$65.3B
$163M 2.95%
4,369,500
-230,000
-5% -$9.36M
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$151M 2.74%
2,012,250
-6,700
-0.3% -$298K
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
$148M 2.69%
6,028,307
– –
UNH icon
8
UnitedHealth
UNH
$344B
$144M 2.62%
281,200
-13,000
-4% -$6.53M
PFE icon
9
Pfizer
PFE
$158B
$144M 2.61%
2,744,000
-1,161,500
-30% -$59.2M
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$12.7B
$141M 2.55%
1,699,710
+52,680
+3% +$4.19M
ABBV icon
11
AbbVie
ABBV
$454B
$122M 2.22%
799,800
-115,800
-13% -$17.7M
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
$122M 2.2%
687,500
+19,800
+3% +$2.85M
EWTX icon
13
Edgewise Therapeutics
EWTX
$4.82B
$112M 2.03%
14,082,680
+138,000
+1% +$1.04M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$132B
$109M 1.98%
387,200
-13,000
-3% -$3.48M
ACET icon
15
Adicet Bio
ACET
$89.1M
$109M 1.97%
465,446
– –
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$108M 1.96%
1,964,770
– –
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$105M 1.9%
719,034
– –
ISRG icon
18
Intuitive Surgical
ISRG
$134B
$104M 1.88%
517,200
-17,000
-3% -$3.99M
ARQT icon
19
Arcutis Biotherapeutics
ARQT
$3B
$102M 1.85%
4,781,646
-1,292,204
-21% -$26.5M
TCDA
20
DELISTED
Tricida, Inc. Common Stock
TCDA
$99.5M 1.8%
10,280,947
– –
EW icon
21
Edwards Lifesciences
EW
$49.3B
$96.2M 1.74%
1,011,300
-40,000
-4% -$4.14M
THRX
22
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$94.2M 1.71%
17,041,668
– –
PMVP icon
23
PMV Pharmaceuticals
PMVP
$74.8M
$93.5M 1.69%
6,563,077
-292,346
-4% -$4.25M
SYK icon
24
Stryker
SYK
$108B
$87.7M 1.59%
441,100
-16,000
-4% -$3.76M
NBIX icon
25
Neurocrine Biosciences
NBIX
$16B
$82.8M 1.5%
849,545
-25,970
-3% -$2.4M
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52B, down 11% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed's Q2 2022 filing shows 15 new, 26 increased, 36 reduced and 15 closed positions. Its largest new stake was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M. The largest sale was DexCom, an estimated $76.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2022 buy was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52B portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.